GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
I

Innocan Pharma INNO.CN · CAD

Health Care · Canadian Securities Exchange · 🇨🇦 Canada

Compare

1.82

—

Close of 5 Nov 2026, in CAD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2024

Revenue

$29.4m

FY2017FY2024

Net income

−$1.8m

FY2017FY2024

Free cash flow

−$1.6m

FY2017FY2024

Shareholders' equity

$5.2m

FY2017FY2024

Income statement

Fiscal years

FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue$29.4m$13.7m$2.6m$196,000$8,000———
Gross profit$26.2m$12.0m$2.1m$121,000$3,000−$117,000−$15,000—
Research and development$1.5m$1.8m$1.5m$1.4m$1.7m$251,000$519,000$11,000
Operating income−$1.2m−$3.8m−$6.3m−$7.5m−$4.7m−$3.0m−$1.2m−$83,000
Net income−$1.8m−$4.7m−$3.8m−$10.0m−$10.0m−$3.3m−$1.2m−$83,000
Diluted earnings per share-0.43-1.19-0.98-2.90-3.99-1.79-0.53-0.03

Balance sheet

At each fiscal year end

FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Total assets$9.3m$6.9m$7.0m$12.6m$4.3m$2.6m$660,000$30,000
Cash and short-term investments$5.0m$3.9m$4.9m$11.0m$2.3m$2.0m$214,000$6,000
Total liabilities$4.1m$2.8m$582,000$3.5m$7.9m$1.2m$533,000$83,000
Debt$10,000$33,000$34,000$1,000$38,000$72,000——
Shareholders' equity$5.2m$4.1m$6.4m$9.1m−$3.6m$1.4m$127,000−$53,000
Shares outstanding4m4m4m3m2m2m2m2m

Cash flow

Fiscal years

FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations−$1.6m−$3.9m−$6.1m−$6.6m−$3.7m−$2.7m−$909,000—
Capital spending−$15,000−$46,000−$26,000−$41,000—−$9,000−$3,000—
Free cash flow−$1.6m−$3.9m−$6.1m−$6.7m−$3.7m−$2.7m−$912,000—

Latest quarters

By quarter end

Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024Jun 2024Mar 2024Dec 2023
Revenue$6.8m$7.0m$7.8m$5.4m$8.6m$8.6m$6.8m$4.9m
Gross profit$6.2m$6.2m$7.1m$4.4m$7.8m$8.0m$6.0m$4.3m
Operating income−$1.2m$396,000$489,000−$919,000$352,000$532,000−$1.2m−$894,000
Net income−$1.9m−$590,000−$582,000−$114,000−$290,000$337,000−$1.8m−$883,000
Diluted earnings per share-0.43-0.13-0.13-0.03-0.060.07-0.42-0.21
Total assets$11.1m$11.0m$10.8m$9.3m$9.6m$8.7m$9.0m$6.9m
Cash and short-term investments$7.3m$7.3m$6.4m$5.0m$5.1m$5.2m$4.6m$3.9m
Debt$1.5m$1.4m$1.3m—$1,000$4,000$7,000$11,000
Shareholders' equity$3.9m$4.2m$4.7m$5.2m$5.2m$4.8m$4.1m$4.1m

Growth per year

Compound annual rate

3 years5 years10 years
Revenue431.6%——
Operating income-45.0%-16.1%—
Net income-43.3%-11.3%—

Average margins

Over each period

1 year3 years5 years10 years
Gross margin88.6%88.1%——
Operating margin-11.7%-41.0%——
Net margin-15.2%-44.4%——

Valuation history

At each fiscal year end

FY2024FY2023FY2022FY2021FY2020FY2019
Price to earnings-14.9-7.9-6.6-8.3-2.5-1.3
Price to sales0.92.79.7426.7——

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 65-to-1 reverse split · 5 Sept 2025

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.